Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial - Test2 - elhamkhani - TriplyDB

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

http://www.wikidata.org/entity/Q24629398

about

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults Rapid antidepressant effects: moving right along Kynurenine pathway metabolites and suicidality Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder Pharmacological Approaches for Treatment-resistant Bipolar Disorder Zinc in the Glutamatergic Theory of Depression Antidepressant mechanism of ketamine: perspective from preclinical studies Review of evidence for use of antidepressants in bipolar depression Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade A review of MR spectroscopy studies of pediatric bipolar disorder Antidepressant actions of ketamine: from molecular mechanisms to clinical practice Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm Emergent treatments based on the pathophysiology of bipolar disorder: A selective review R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression Treatment of bipolar disorder Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice Options for Pharmacological Treatment of Refractory Bipolar Depression GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats.Animal models to improve our understanding and treatment of suicidal behavior Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.Do the dissociative side effects of ketamine mediate its antidepressant effects?Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature Existing and novel biological therapeutics in suicide prevention.Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior.A randomized controlled trial of intranasal ketamine in major depressive disorder.A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

P2860

Q22252957-B70E70F4-4DB1-4D96-80EE-8D1B009C5822 Q24614410-9EDC115B-2E8F-4AE2-AB28-CA3EC0994431 Q26773067-60C3ADCC-4981-4151-AC55-0EEC27D98F6F Q26782274-A06FE974-77B2-43B8-A7BF-3468B33F8FD7 Q26782989-EBD011B3-3C1D-4182-ABEA-67D7F5A2FB4C Q26783002-3B757231-F1ED-4734-B2F3-75D0B263A82B Q26786214-D5C2F4FA-0AD3-4224-B610-C6EF129D191D Q26800231-4D5466EA-0788-4948-824C-E9E3815CF042 Q26824365-3071D66A-C6F5-4311-8F16-A270944FAD19 Q26829556-F2995DE7-735B-410A-AC6A-71A99EA26D0E Q26850084-DB7D2E9F-6843-45A1-9000-3137800C8F17 Q26991430-3900AD24-5AA5-4C69-AA78-976F058ABAD5 Q26995879-F80175E9-4FAE-4CAA-AAB8-D6B626AB6F60 Q27004490-D462505D-7037-4707-BB63-47927B5B4960 Q27024227-F8381DBA-0201-4268-94C6-7015D1A48E72 Q28066714-E972A7DE-5600-471B-A351-ED6753424184 Q28082445-50472669-6803-41C6-AF8C-DE8F5A333441 Q28266846-03842C36-EF93-476A-B954-787C252DE3DF Q28277636-8E7F9D06-8F7B-42F4-BEB7-7BC173433FD5 Q28290437-3BEE9833-3256-4932-9436-3E77CCFF099F Q28485938-989A93D6-F975-4819-AC98-46B67A8E0B4E Q29395337-DBD4F458-9496-494D-B959-2F4E950D9AED Q30440925-93372F69-3720-494F-A62D-B74673F1CCEB Q30852008-C51BEA1E-2F69-45E7-B115-FE1F586BE07F Q33635653-B2A3B57B-6341-47F2-908C-73E415536934 Q33758450-E59540B8-0B54-41D7-AEA1-ED8A3060439C Q33787133-29BE234C-41C0-4066-9C52-77E898353B46 Q33874459-7C733BAA-646A-4A36-B09E-271E8BB16122 Q33956313-F4A9133F-CE9F-4087-841E-310536C2CF56 Q34043478-13192963-5507-49C2-B5DA-2317839C36BD Q34085866-60B6C13C-2972-4E7C-B269-AE9F51CF9822 Q34177760-15850ED7-EF7B-46DF-AB40-93A6CCC4E9D9 Q34241455-E52D5BE3-1185-443D-BC33-BDE477C4A340 Q34268501-88115783-9BD1-4AD2-BF97-1C24EB4A58A6 Q34273623-80D575F9-DAAE-43E4-AA58-8FCE9C4873C0 Q34288196-AC5CE7BB-7AB3-4608-9FE1-D8D506CDACF0 Q34315128-4C35D6E0-8845-4F60-BA15-AE3BCA089A38 Q34330678-B3F0BA9D-0D78-45DE-9E40-A6ACB3EFE794 Q34333515-E44EE094-A764-4CCD-8607-64B3CF0AD56D Q34349641-56554F39-F244-4054-AF7C-DA32274F43A8

P2860

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

http://www.wikidata.org/entity/Q24629398

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Replication of ketamine's anti ...... omized controlled add-on trial

@ast

Replication of ketamine's anti ...... omized controlled add-on trial

@en

Replication of ketamine's anti ...... omized controlled add-on trial

@nl

type

label

Replication of ketamine's anti ...... omized controlled add-on trial

@ast

Replication of ketamine's anti ...... omized controlled add-on trial

@en

Replication of ketamine's anti ...... omized controlled add-on trial

@nl

prefLabel

Replication of ketamine's anti ...... omized controlled add-on trial

@ast

Replication of ketamine's anti ...... omized controlled add-on trial

@en

Replication of ketamine's anti ...... omized controlled add-on trial

@nl

P1433

Q24629398-2C8F6AC3-ADDD-4488-A5EF-95698D4220C4

P1476

Q24629398-1BD380D6-3468-4F21-B1F2-9DEA94FDAF9A

P2093

Q24629398-320A5295-E7A3-4FA4-9436-F112837FFBB6

Q24629398-465B0AA8-B275-40ED-9086-E1027EC24515

Q24629398-5F33A0E6-C7BD-46C2-AD10-C2824B60AF7A

Q24629398-689812F4-520A-436F-8949-D63FEF32CAAA

Q24629398-6F78DA16-5425-44BC-BD03-537054B25ED5

Q24629398-A94B80DD-F790-4555-9D8B-C7E7B7849133

Q24629398-B600014A-CA4E-4B45-937C-A4EA3A54E330

Q24629398-CFA7707A-4A38-46FF-BC7C-3E549087108A

Q24629398-E9314BA3-EAAE-4B3A-9BA3-8592D595CA54

P2860

Q24629398-0554A7C8-2146-4F51-B123-7EEAB5932098

Q24629398-0708FF13-9673-466C-A802-9B23481BF39B

Q24629398-07A80D32-EAB6-4D83-85BA-6FFE621352E1

Q24629398-0BFE63C5-02EE-464B-B23B-988F7524A3BE

Q24629398-12495046-0E31-4818-88FF-7C589E5A6490

Q24629398-15F3B80F-8775-4810-A0CE-CA774BA77E92

Q24629398-1B96E91B-97B3-40C4-A6AB-790EF4A56982

Q24629398-26FEFDDB-7AF4-41DB-A254-BBE87BFAE318

Q24629398-2D64D559-9B2A-4489-A75E-6C6F4D4D973D

Q24629398-2F48345C-DE74-482A-88E1-75955B6FE41C

P304

Q24629398-7082BA6E-FA0D-4ABA-91AB-3887CCCC6D18

P31

Q24629398-5FA587FB-B7D7-41F4-BABD-047A6FF49A37

P3181

Q24629398-61DE1462-ED05-4204-BE16-A1688314A88E

P356

Q24629398-3A149EEB-3C3F-4650-BBF1-FDF4944F8C25

P407

Q24629398-E6A3E8FB-A100-4AC7-A3EB-D70624B25F05

P433

Q24629398-E15BCD66-D691-42FB-A82B-8BDA02C96C94

P478

Q24629398-123D1FF3-FEBC-4418-AD6E-DA9130124DDC

P50

Q24629398-61B6C1AD-6232-4091-8F0B-D3B42D1094C0

P577

Q24629398-5F63A40C-992B-4F25-9E1E-E7DC047D5333

P5875

Q24629398-26DCDCEA-A7B8-47BE-A051-927921EFFECC

P698

Q24629398-12CF4A5E-E418-4425-8D71-B13167388BD0

P932

Q24629398-6F14704B-A5F7-4C16-91E6-3E48A0AB294F

P3181

P356

J.BIOPSYCH.2011.12.010

P1433

Biological Psychiatry

P1476

Replication of ketamine's anti ...... omized controlled add-on trial

@en

P2093

Anibal Cravchik

http://www.w3.org/2001/XMLSchema#string

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Craig A Marquardt

http://www.w3.org/2001/XMLSchema#string

David A Luckenbaugh

http://www.w3.org/2001/XMLSchema#string

Jessica Selter

http://www.w3.org/2001/XMLSchema#string

Jose Franco-Chaves

http://www.w3.org/2001/XMLSchema#string

Lobna Ibrahim

http://www.w3.org/2001/XMLSchema#string

Nancy E Brutsche

http://www.w3.org/2001/XMLSchema#string

Victoria Liberty

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys

The assessment of anxiety states by rating

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

A rating scale for mania: reliability, validity and sensitivity

P304

939-946

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

573270

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BIOPSYCH.2011.12.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Nancy Diazgranados

P577

2012-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221798202

http://www.w3.org/2001/XMLSchema#string

P698

22297150

http://www.w3.org/2001/XMLSchema#string

P932

3343177

http://www.w3.org/2001/XMLSchema#string